103 related articles for article (PubMed ID: 3988128)
1. Serum-mediated immunosuppression: a possible tumor marker in patients with ovarian carcinoma.
Onsrud M
Gynecol Oncol; 1985 May; 21(1):94-100. PubMed ID: 3988128
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive effects of peritoneal fluids from ovarian cancer patients.
Onsrud M
Gynecol Oncol; 1986 Mar; 23(3):316-22. PubMed ID: 3957117
[TBL] [Abstract][Full Text] [Related]
3. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of serum immunosuppressive effect in patients with ovarian cancer.
Ueda K; Toyokawa M; Nakamori H; Sako H; Umesaki N; Nakade J; Lee T; Sugawa T
Obstet Gynecol; 1979 Apr; 53(4):480-3. PubMed ID: 440651
[TBL] [Abstract][Full Text] [Related]
5. Suppressive serum, suppressor lymphocytes, and death from burns.
Wolfe JH; Saporoschetz I; Young AE; O'Connor NE; Mannick JA
Ann Surg; 1981 Apr; 193(4):513-20. PubMed ID: 6452102
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive factors in ascites fluids from ovarian cancer patients.
Fumita Y; Tanaka F; Saji F; Nakamuro K
Am J Reprod Immunol (1980); 1984 Dec; 6(4):175-8. PubMed ID: 6528882
[TBL] [Abstract][Full Text] [Related]
7. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
8. Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy.
Jha P; Farooq A; Rao DL; Agarwal N; Buckshee K
Int J Gynaecol Obstet; 1991 Sep; 36(1):33-8. PubMed ID: 1683299
[TBL] [Abstract][Full Text] [Related]
9. [Effect of the lymphocytes of endometriosis patients on the growth of HeLa cell colonies].
Startseva NV; Shvetsov MV
Akush Ginekol (Mosk); 1983 Nov; (11):53-5. PubMed ID: 6666803
[No Abstract] [Full Text] [Related]
10. Synergistic effects of cyclosporine and rabbit antithymocyte sera on suppression of the one-way allogeneic mixed lymphocyte response.
Brady HR; Peters P; Cardella CJ
Transplant Proc; 1988 Apr; 20(2 Suppl 2):229-32. PubMed ID: 2966478
[No Abstract] [Full Text] [Related]
11. [Sequential determination of circulating immune complexes in ovarian tumors].
Beaufort F; Auner H; Lahousen M
Wien Med Wochenschr; 1986 Jul; 136(13):317-22. PubMed ID: 3765649
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
Sevelda P; Salzer H; Dittrich C; Spona J
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
[TBL] [Abstract][Full Text] [Related]
13. [Second-look and third-look laparotomies in follow-up of ovarian cancer. A critical review of 6 years' experience].
Schneider J; Erasun F; Hervas JL; Miñambres JL
Zentralbl Gynakol; 1987; 109(4):235-42. PubMed ID: 3591059
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients.
Boyer PJ; Berek JS; Zighelboim J
Obstet Gynecol; 1989 May; 73(5 Pt 1):793-7. PubMed ID: 2784847
[TBL] [Abstract][Full Text] [Related]
15. Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells.
Papadopoulos AJ; Han X; Matossian-Rogers A; Raju KS
Gynecol Oncol; 1995 Jun; 57(3):388-94. PubMed ID: 7774843
[TBL] [Abstract][Full Text] [Related]
16. [Tumor marker combination versus second-look operation in ovarian cancer].
Lahousen M; Stettner H; Pürstner P; Pickel H
Zentralbl Gynakol; 1990; 112(9):561-6. PubMed ID: 2378187
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125.
Högberg T; Kågedal B
Gynecol Oncol; 1992 Aug; 46(2):191-8. PubMed ID: 1500022
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the role of second-look surgery in ovarian cancer.
Chambers SK; Chambers JT; Kohorn EI; Lawrence R; Schwartz PE
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):404-8. PubMed ID: 3405557
[TBL] [Abstract][Full Text] [Related]
19. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
Mallmann P; Krebs D
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
[TBL] [Abstract][Full Text] [Related]
20. Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma.
Zanaboni F; Vergadoro F; Presti M; Gallotti P; Lombardi F; Bolis G
Gynecol Oncol; 1987 Sep; 28(1):61-7. PubMed ID: 2443433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
